CHTP Chelsea Therapeutics International, Ltd. featured news, full reports, and detailed charts
Chelsea Therapeutics International, Ltd. (CHTP) Wrap Up:
We are a development stage pharmaceutical company that seeks to acquire and develop innovative products for the treatment of a variety of human diseases. Our strategy is to develop technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Specifically, we concentrate our efforts on acquiring and developing technologies for the treatment of rheumatoid arthritis, autonomic nervous system conditions, psoriasis, inflammatory bowel disease, cancer and other disorders or technologies that will compliment this core focus. Product Pipeline Summary Currently, we are currently developing two platform technologies that each consist of a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f11%2f0001193125-08-052916.html#FIS_BUSINESS"Chelsea Therapeutics International Ltd. (CHTP:NASDAQ)
Snapshot of Chelsea Therapeutics International Ltd. (CHTP)
|
OPEN
$2.25
|
PREVIOUS CLOSE
$2.28
|
|
|
DAY HIGH
$2.30
|
DAY LOW
$2.25
|
|
|
52 WEEK HIGH
09/14/09 - $7.51
|
52 WEEK LOW
12/12/08 - $1.09
|
|
|
MARKET CAP
76.0M
|
AVERAGE VOLUME 3 mo
330.1K
|
|
|
DILUTED EPS TTM
$-0.94
|
SHARES OUTSTANDING
33.5M
|
|
|
CHTP Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
CHTP Top Compensated Officers
Executives, Board Directors
Key developments for Chelsea Therapeutics International Ltd. (CHTP)
Chelsea Therapeutics International Ltd. reported financial results for the third quarter and nine months ended Sep. 30, 2009. For the quarter, net loss was $7.1 million or ($0.22) per share versus a net loss of $10.1 million or ($0.34) per share for the same period in 2008. The net loss for the third quarter of 2008 included an impairment charge of $2.1 million, or ($0.07) per share related to student loan backed auction rate securities (ARS), excluding this 2008 impairment charge and on a non-GAAP basis, net loss of $7.1 million for the third quarter of 2009 compares to a net loss of $8.0 million or ($0.27) per share for the comparable prior year period. For the first nine months of 2009, the company reported a net loss of $19.8 million or ($0.64) per share compared to a net loss of $26.1 million or ($0.87) per share for the first half of 2008. Excluding the 2008 ARS impairment charges and the associated gain in 2009, Chelsea's net loss, on a non-GAAP basis, of $24.2 million for the first nine months of 2009 increased by approximately $1.8 million from the net loss of $22.4 million for the prior-year period.
Chelsea Therapeutics International Ltd. announced the appointment of William D. Schwieterman, M.D., to the newly created position of Chief Medical Officer. Dr. Schwieterman, who resigned his seat on Chelsea's Board of Directors to assume the position, will be responsible for medical and regulatory affairs, and will report to Simon Pedder, Ph.D., Chelsea's President and Chief Executive Officer. Dr. Schwieterman, a rheumatologist and board-certified internist, brings over 25 years of experience to Chelsea with a career spanning medical practice, drug development, and regulatory oversight. For the past year, Dr. Schwieterman held a seat on Chelsea's Board of Directors following three years of service on the Company's rheumatology advisory board.
Chelsea Therapeutics International Ltd. expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on November 2, 2009).
CHTP Competitors
| Company | Last | Change |
| Adeona Pharmaceuticals Inc | $0.55 USD | -0.0199 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CHTP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 4.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
CHTP |
||
CHTP transactions
| Type Date |
Target |
|
Private Placement
July 22, 2009 |
-- |